Kenvue (Kenvue) Cash And Cash Equivalents : $1,155 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Kenvue Cash And Cash Equivalents?

Kenvue's quarterly cash and cash equivalents increased from Sep. 2023 ($1,062.00 Mil) to Dec. 2023 ($1,382.00 Mil) but then stayed the same from Dec. 2023 ($1,382.00 Mil) to Mar. 2024 ($1,155.00 Mil).

Kenvue's annual cash and cash equivalents increased from Dec. 2021 ($740.00 Mil) to Dec. 2022 ($1,231.00 Mil) and increased from Dec. 2022 ($1,231.00 Mil) to Dec. 2023 ($1,382.00 Mil).

Kenvue Cash And Cash Equivalents Historical Data

The historical data trend for Kenvue's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kenvue Cash And Cash Equivalents Chart

Kenvue Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

618.00

740.00

1,231.00

1,382.00

Kenvue Quarterly Data
	Dec19	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial								1,691.00	1,231.00	1,062.00	1,382.00	1,155.00

Kenvue Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Kenvue (NYSE:KVUE) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Kenvue Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Kenvue's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Kenvue (Kenvue) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Kenvue Inc (NYSE:KVUE) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

J4D:Germany J4D:Germany J4D:Germany

Address

199 Grandview Road, Skillman, NJ, USA, 08558

Website

https://www.kenvue.com

Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.

Executives

Allison Richard E Jr	director	30 FRANK LLOYD WRIGHT DR, ANN ARBOR MI 48105
Seemantini Godbole	director	1000 LOWE'S BOULEVARD, MOORESVILLE NC 28117
Bing Xie	officer: Group President, Asia Pacific	199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Donna Lorenson	officer: Chief Corp Affairs Officer	199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Matthew Orlando	officer: General Counsel	199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Luani Alvarado	officer: Chief People Officer	199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Jan Meurer	officer: Chief Growth Officer	199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Carlton Lawson	officer: Group President, EMEA	199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Caroline Tillett	officer: Chief Scientific Officer	199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Bernardo Tavares	officer: Chief Tech & Data Officer	199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Tamara Franklin	director	107 STONE CLIFF ROAD, PRINCETON NJ 08540
Betsy D Holden	director	DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kathy Widmer	officer: Group President, NALA	C/O ELIZABETH ARDEN, INC., 2400 S.W. 145 AVENUE, MIRAMAR FL 33027
Michael E Sneed	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Joseph J Wolk	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933